Skip to main content

Table 3 Indications and therapeutic interventions

From: Safety, risk stratification, and cost of ERCP in patients with cirrhosis: a prospective controlled study

 

Cirrhotic (n = 150)

Non-cirrhotic (n = 150)

χ2

P

No.

%

No.

%

Cause of obstruction:

      

 Calcular

80

53.3

109

72.7

12.026*

0.001*

 CBD malignant stricture

56

37.3

34

22.6

6.144*

0.01/3*

 CHD malignant stricture

20

13.4

5

3.4

7.714*

0.005*

 Primary sclerosing cholangitis

2

1.3

0

0.0

2.013

FEp = 0.498

 Igg4 syndrome

0

0.0

2

1.3

2.013

FEp = 0.-498

 Mirizzi syndrome

1

0.7

0

0.0

1.003

FEp = 1.000

Intervention

      

 Failed cannulation

3

2.0

2

1.3

0.226

FEp = 0.681

 Papillotomy

44

29.3

81

54.0

18.775*

< 0.001*

 Papilloplasty

0

0.0

9

6.0

9.278*

FEp = 0.003

 Plastic stent

117

78.0

90

60.0

11.360*

0.001*

 Metal stent

13

8.7

5

3.3

3.783

0.052

 Stone extraction

16

10.7

57

38.0

30.433*

< 0.001*

 Precut

4

2.7

6

4.0

0.414

0.520

  1. CBD Common bile duct, CHD Common hepatic duct
  2. *significante